Abstract According to the Alzheimer Association Report (2017), Alzheimer's disease (AD) is
the 6th primary cause of death in the USA, which affects nearly 5.5 million people. In the …

Abstract Nose-to-brain (N-to-B) delivery offers to protein and peptide drugs the possibility to
reach the brain in a non-invasive way. This article is a comprehensive review of the state-of …

Erythropoietin (EPO) is a cytokine mainly induced in hypoxia conditions. Its major production
site is the kidney. EPO primarily acts on the erythroid progenitor cells in the bone marrow …

In view of the rapid preclinical development of cell-based therapies for neurodegenerative
disorders, traumatic brain injury, and tumors, the safe and efficient delivery and targeting of …

Erythropoietin (Epo), the main erythropoiesis‐stimulating factor widely prescribed to
overcome anemia, is also known nowadays for its cytoprotective action on non …

It has been accepted that kidney function is connected with brain activity. In clinical studies,
chronic kidney disease (CKD) patients have been found to be prone to suffering cognitive …

Numerous studies explored the therapeutic effects of erythropoietin (EPO) on
neurodegenerative diseases. Few studies provided comprehensive and latest knowledge of …

Intranasal drug administration is a promising method for delivering drugs directly to the
brain. Animal studies have described pathways and potential brain targets, but nose-to-brain …

Acute as well as chronic disorders of the nervous system lead to significant morbidity and
mortality for millions of individuals globally. Given the ability to govern stem cell proliferation …

Erythropoietin (EPO) is a cytokine known to have effective cytoprotective action in the brain,
particularly in ischemic, traumatic, inflammatory, and neurodegenerative conditions. We …